ReviewAntibiotics (Basel, Switzerland)2022
Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Comparative effectiveness and safety of vancomycin versus linezolid for the treatment of central nervous system infections: a meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Piperacillin Population Pharmacokinetics in Plasma and Peritoneal Fluid and Dosing Optimization in Children Undergoing Liver Transplant: An Optimome Study.Clinical pharmacology and therapeutics · 2026Observational
- A Pharmacist-Driven Closed-Loop Stewardship Model of Meropenem: Impact on Stability and Efficacy in Neurosurgery Patients.Drug design, development and therapy · 2026Article
- Impact of an antimicrobial stewardship-based infection prevention bundle on postoperative central nervous system infection in a tertiary neurosurgery department: a quasi-experimental study.Frontiers in pharmacology · 2026Article
- Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance.Interdisciplinary perspectives on infectious diseases · 2026Review
- Morphological and Molecular Identification ofClinical case reports · 2025Article
- Management of meningitis in critical obstetric patients: a case report.Journal of medical case reports · 2025Article
- An In Vitro Calibration Model for Vancomycin Quantification in Brain Extracellular Fluid: Toward Improved Dosing in Postoperative Infections.Pharmacology research & perspectives · 2025Article
- A spatial transcriptomics study of MES-like and mono/macro cells in gliomas.Scientific reports · 2025Article
- Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection.European journal of hospital pharmacy : science and practice · 2024Article
- A Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneously Determining Meropenem and Linezolid in Blood and Cerebrospinal Fluid.Annals of laboratory medicine · 2024Article
- Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs.Antibiotics (Basel, Switzerland) · 2023Article
- External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients.European journal of clinical pharmacology · 2023Article
- Comparison of Intravenous Microdialysis and Standard Plasma Sampling for Monitoring of Vancomycin and Meropenem Plasma Concentrations-An Experimental Porcine Study.Antibiotics (Basel, Switzerland) · 2023Article
- A High-Performance Liquid Chromatography-Mass Spectrometry Method for Simultaneous Determination of Vancomycin, Meropenem, and Valproate in Patients with Post-Craniotomy Infection.Molecules (Basel, Switzerland) · 2023Article
- Evaluation and Analysis of the Rationality of Clinical Use of Carbapenems in Surgical Departments of a Tertiary Hospital in Southwest China.Infection and drug resistance · 2023Article
- The Clinical Characteristics, Diagnostic Methods, Treatment, and Outcomes ofInfection and drug resistance · 2023Article
- The Blood-Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults.Antibiotics (Basel, Switzerland) · 2022Review
- A carbapenem antibiotic inhibiting a mammalian serine protease: structure of the acylaminoacyl peptidase-meropenem complex.Chemical science · 2022Article
- Membrane Vesicles Derived from Gut Microbiota and Probiotics: Cutting-Edge Therapeutic Approaches for Multidrug-Resistant Superbugs Linked to Neurological Anomalies.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current antimicrobial therapy of bacterial infections of the central nervous system (CNS) in adults and pediatric patients is faced with many pitfalls as the drugs have to reach necessary levels in serum and cross the blood-brain barrier. Furthermore, several studies report that different factors such as the structure of the antimicrobial agent, the severity of disease, or the degree of inflammation play a significant role. Despite the available attempts to establish pharmacokinetic (PK) modeling to improve the required dosing regimen for adults and pediatric patients, conclusive recommendations for the best therapeutic strategies are still lacking. For instance, bacterial meningitis, the most common CNS infections, and ventriculitis, a severe complication of meningitis, are still associated with 10% and 30% mortality, respectively. Several studies report on the use of vancomycin and meropenem to manage meningitis and ventriculitis; therefore, this review aims to shed light on the current knowledge about their use in adults and pediatric patients. Consequently, studies published from 2015 until mid-July 2021 are included, and data about the study population, levels of drugs in serum and cerebrospinal fluid (CSF), and measured PK data in serum and CSF are provided. The overall aim is to provide the readers a recent reference that summarizes the pitfalls and success of the current therapy and emphasizes the importance of performing more studies to improve the clinical outcome of the current therapeutical approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.